Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 8/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724400 | 1.00 | KMT2A (0.43) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL19199495 | 0.88 | CASP1 (0.47) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL19194321 | 0.88 | CASP1 (0.47) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL1299623 | 0.88 | CASP1 (0.47) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL1299624 | 0.88 | CASP1 (0.47) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL1299626 | 0.88 | CASP1 (0.47) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL31654805 | 0.84 | NFKB1 (0.39) | KMT2AL3MBTL1FKBP1ANFKB1NFKB2 | |
| SCHEMBL31654108 | 0.83 | NFKB1 (0.40) | KMT2AL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL12109063 | 0.83 | FKBP1A (0.43) | KMT2AL3MBTL1FKBP1ACTSLCASP1 | |
| SCHEMBL9973474 | 0.81 | CASP1 (0.54) | KMT2AL3MBTL1FKBP1ACTSLCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | KMT2A 3553/4885L3MBTL1 99/4885FKBP1A 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.